Meher R Juttukonda1,2,3, Larry T Davis3, Sarah K Lants3, Spencer L Waddle3, Chelsea A Lee3, Niral J Patel3, Lori C Jordan3,4,5, Manus J Donahue3,5,6. 1. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts, USA. 2. Department of Radiology, Harvard Medical School, Boston, Massachusetts, USA. 3. Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 4. Department of Pediatrics, Division of Pediatric Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 5. Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 6. Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abstract
BACKGROUND: Patients with symptomatic atherosclerotic and non-atherosclerotic (i.e., moyamoya) intracranial steno-occlusive disease experience high 2-year infarct rates. PURPOSE: To investigate whether cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) measures may provide biomarkers of 1-to-2-year infarct risk. STUDY TYPE: Prospective, longitudinal study. SUBJECTS: Adult participants (age = 18-85 years) with symptomatic intracranial atherosclerotic disease (N = 26) or non-atherosclerotic (i.e., moyamoya; N = 43) and stenosis ≥50% of a major intracranial artery were initially scanned within 45 days of stroke. Follow-up imaging (target = 1.5 years) was acquired for new infarct assessment. FIELD STRENGTH/SEQUENCE: 3.0 Tesla with normocapnic arterial spin labeling (ASL) and blood oxygenation level-dependent (BOLD) imaging acquired during an interleaved hypercapnic (3 minutes) and normocapnic (3 minutes) respiratory stimulus. ASSESSMENT: CBF, maximum CVR, and time-to-maximum CVR (i.e., CVRDELAY ) were calculated. Laterality indices (difference between infarcted and contralesional hemispheres divided by sum of absolute values) of metrics at enrollment were contrasted between participants with vs. without new infarcts on follow-up. STATISTICAL TESTS: Laterality indices were compared using non-parametric Wilcoxon tests (significance: two-sided P < 0.05) and effect sizes as Cohen's d. Continuous variables are presented as mean ± SD. RESULTS: New infarcts were observed on follow-up in 15.0% of participants. The laterality index of the CVRDELAY was elevated (P = 0.01) in participants with atherosclerosis with new infarcts (index = 0.13) compared to participants without new infarcts (index = 0.05). DATA CONCLUSION: Elevated CVRDELAY may indicate brain parenchyma at increased risk for new infarcts in patients with symptomatic intracranial atherosclerotic disease treated with standard-of-care medical management. LEVEL OF EVIDENCE: 2 TECHNICAL EFFICACY STAGE: 3.
BACKGROUND: Patients with symptomatic atherosclerotic and non-atherosclerotic (i.e., moyamoya) intracranial steno-occlusive disease experience high 2-year infarct rates. PURPOSE: To investigate whether cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) measures may provide biomarkers of 1-to-2-year infarct risk. STUDY TYPE: Prospective, longitudinal study. SUBJECTS: Adult participants (age = 18-85 years) with symptomatic intracranial atherosclerotic disease (N = 26) or non-atherosclerotic (i.e., moyamoya; N = 43) and stenosis ≥50% of a major intracranial artery were initially scanned within 45 days of stroke. Follow-up imaging (target = 1.5 years) was acquired for new infarct assessment. FIELD STRENGTH/SEQUENCE: 3.0 Tesla with normocapnic arterial spin labeling (ASL) and blood oxygenation level-dependent (BOLD) imaging acquired during an interleaved hypercapnic (3 minutes) and normocapnic (3 minutes) respiratory stimulus. ASSESSMENT: CBF, maximum CVR, and time-to-maximum CVR (i.e., CVRDELAY ) were calculated. Laterality indices (difference between infarcted and contralesional hemispheres divided by sum of absolute values) of metrics at enrollment were contrasted between participants with vs. without new infarcts on follow-up. STATISTICAL TESTS: Laterality indices were compared using non-parametric Wilcoxon tests (significance: two-sided P < 0.05) and effect sizes as Cohen's d. Continuous variables are presented as mean ± SD. RESULTS: New infarcts were observed on follow-up in 15.0% of participants. The laterality index of the CVRDELAY was elevated (P = 0.01) in participants with atherosclerosis with new infarcts (index = 0.13) compared to participants without new infarcts (index = 0.05). DATA CONCLUSION: Elevated CVRDELAY may indicate brain parenchyma at increased risk for new infarcts in patients with symptomatic intracranial atherosclerotic disease treated with standard-of-care medical management. LEVEL OF EVIDENCE: 2 TECHNICAL EFFICACY STAGE: 3.
Authors: Robert M Starke; Ricardo J Komotar; Zachary L Hickman; Yehuda E Paz; Angela G Pugliese; Marc L Otten; Matthew C Garrett; Mitchell S V Elkind; Randolph S Marshall; Joanne R Festa; Philip M Meyers; E Sander Connolly Journal: J Neurosurg Date: 2009-11 Impact factor: 5.115
Authors: C Heyn; J Poublanc; A Crawley; D Mandell; J S Han; M Tymianski; K terBrugge; J A Fisher; D J Mikulis Journal: AJNR Am J Neuroradiol Date: 2010-01-14 Impact factor: 3.825
Authors: Ashley M Wabnitz; Colin P Derdeyn; David J Fiorella; Michael J Lynn; George A Cotsonis; David S Liebeskind; Michael F Waters; Helmi Lutsep; Elena López-Cancio; Tanya N Turan; Jean Montgomery; L Scott Janis; Bethany Lane; Marc I Chimowitz Journal: Stroke Date: 2018-12-11 Impact factor: 7.914
Authors: Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: Spencer L Waddle; Meher R Juttukonda; Sarah K Lants; Larry T Davis; Rohan Chitale; Matthew R Fusco; Lori C Jordan; Manus J Donahue Journal: J Cereb Blood Flow Metab Date: 2019-05-08 Impact factor: 6.200
Authors: Meher R Juttukonda; Binyin Li; Randa Almaktoum; Kimberly A Stephens; Kathryn M Yochim; Essa Yacoub; Randy L Buckner; David H Salat Journal: Neuroimage Date: 2021-01-29 Impact factor: 7.400
Authors: Julien Poublanc; Jay Show Han; Daniel Michael Mandell; John Conklin; Jeffrey Alan Stainsby; Joseph Arnold Fisher; David John Mikulis; Adrian Philip Crawley Journal: Cerebrovasc Dis Extra Date: 2013-04-12